Personalizing Care in MG

EP: 1.Presentation of Myasthenia Gravis (MG)

EP: 2.Fatigue and Fluctuating Symptoms in MG

EP: 3.Accurate Diagnosis of MG

EP: 4.Hospitalization of Older Patients in MG

EP: 5.Treatment Approach in MG

EP: 6.Quality of Life in MG

EP: 7.Targeted Therapy Options in MG

EP: 8.Use of Targeted Therapies in the Treatment Algorithm of MG

EP: 9.Modes of Administration for Targeted Treatment in MG

EP: 10.Switching MG Treatment Due to Adverse Events or Poor Disease Control

EP: 11.Treatment Adherence in MG

EP: 12.Emerging Treatments in MG

Now Viewing

EP: 13.Personalizing Care in MG

EP: 14.The Pharmacist’s Role in MG Management

EP: 15.Improving Patient Communication in MG

This is a video synopsis/summary of a panel discussion involving James Howard, MD; Nicholas Silvestri, MD, FAAN; Tuan Vu, MD; Ali Habib, MD; and Beth Stein, MD.

The conversation shifts to the effectiveness of targeted therapies in personalizing patient care for patients with myasthenia gravis (MG). Participants discuss the challenges of incorporating these therapies alongside existing treatments and effectively communicating options to patients. They emphasize the importance of breaking down complex information into manageable parts for both patients and providers.

Clinical trial participation is highlighted as crucial for advancing therapies, with recognition of patients' contributions and the benefits of improved access to care. However, there's concern about disparities in trial recruitment, particularly in North America, and the need for better outreach and adaptation of trial methodologies to ensure inclusivity.

The looming concern is whether current practices can sustain the demand for new therapies, given the growing pipeline and conceptualized treatments. This prompts a call for reflection on trial recruitment practices and potential regulatory hurdles to ensure continued progress in patient care.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.